The effect of methotrexate on the expression of cell adhesion molecules and activation molecule CD69 in psoriasis

Journal of the European Academy of Dermatology and Venereology

Volumn 21, Issue 3, 2007, Pages 334-339

  Torres Alvarez B ^a   Castanedo Cazares, J P ^a   Fuentes Ahumada, C ^a   Moncada, B ^a  

^a UNIVERSIDAD AUTÓNOMA DE SAN LUIS POTOSÍ   (Mexico)

Author keywords

CD69; Cell adhesion molecules; Methotrexate; Psoriasis

Indexed keywords

CD4 ANTIGEN; CD69 ANTIGEN; CD8 ANTIGEN; CELL ADHESION MOLECULE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; INTERCELLULAR ADHESION MOLECULE 1; METHOTREXATE; VASCULAR CELL ADHESION MOLECULE 1;

ABSENCE OF SIDE EFFECTS; ADULT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; DERMIS; DISEASE SEVERITY; DOWN REGULATION; DRUG EFFECT; DRUG MECHANISM; EPIDERMIS; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KERATINOCYTE; LYMPHOCYTIC INFILTRATION; MALE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PSORIASIS; RECURRENT DISEASE; SKIN BIOPSY; T LYMPHOCYTE;

ADULT; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, T-LYMPHOCYTE; BIOPSY; CELL ADHESION MOLECULES; DERMATOLOGIC AGENTS; DOWN-REGULATION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; METHOTREXATE; MIDDLE AGED; PHENOTYPE; PSORIASIS;

EID: 33846966308     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2006.01916.x     Document Type: Article

References (28)

1. Nickoloff BJ, Nestle FO. Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities. J Clin Invest 2004; 113: 1664-1675.
2. Nickoloff BJ. The cytokine network in psoriasis. Arch Dermatol 1991; 127: 871-884.
3. Skov L, Kragballe K, Zachariae C et al. HuMax-CD4: A fully human monoclonal anti-CD4 antibody for the treatment of psoriasis vulgaris. Arch Dermatol 2003; 139: 1433-1439.
4. Bagel J, Garland WT, Breneman D et al. Administration of DAB389IL-2 to patients with recalcitrant psoriasis: A double-blind, phase II multicenter trial. J Am Acad Dermatol 1998; 38: 938-944.
5. Ho VC, Griffiths CE, Berth-Jones J et al. Intermittent short courses of cyclosporine microemulsion for the long-term management of psoriasis: A 2-year cohort study. J Am Acad Dermatol 2001; 44: 643-651.
6. Freeman AK, Linowski GJ, Brady C et al. Tacrolimus ointment for the treatment of psoriasis on the face and intertriginous areas. J Am Acad Dermatol 2003; 48: 564-568.
7. Krueger JG. The immunologic lesions basis for the treatment of psoriasis with new biologic agents. J Am Acad Dermatol 2002; 46: 1-23.
8. Veale D, Rogers S, Fitzgerald O. Immunolocalization of adhesion molecules in psoriatic arthritis, psoriatic and normal skin. Br J Dermatol 1995; 132: 32-38.
9. Uyemura K, Yamamura M, Fivenson DF et al. The cytokine network in lesional and lesion-free psoriatic skin is characterized by a T-helper type 1 cell-mediated response. J Invest Dermatol 1993; 101: 701-705.
10. Heydendael MRV, Spuls IP, Opmeer CB et al. Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis. N Engl J Med 2003; 349: 658-665.
11. Saporito FC, Menter MA. Methotrexate and psoriasis in the new era of new biologic agents. J Am Acad Dermatol 2004; 50: 301-309.
12. Sigmundsdottir H, Johnston A, Gudjonsson JE. Methotrexate markedly reduces the expression of vascular E-selectin and CLA and the numbers of mononuclear leucocytes in psoriatic skin. Exp Dermatol 2004; 13: 426-434.
13. Yazici AC, Tursen U, Apa DD et al. The changes in expression of ICAM-3, ki-67, PCNA and CD31 in psoriatic lesions before and after methotrexate treatment. Arch Dermatol Res 2005; 297: 249-255.
14. Johnston A, Gudjonsson JE, Sigmundsdottir H et al. The anti-inflammatory action of methotrexate is not mediated by lymphocyte apoptosis, but by the suppression of activation and adhesion molecules. Clin Immunol 2005; 114: 154-163.
15. Cosulich ME, Rubartelli A, Risso A et al. Functional characterization of an antigen involved in an early step of T-cell activation. Proc Natl Acad Sci USA 1987; 84: 4205-4209.
16. Sanchez-Mateos P, Cebrian M, Acevedo A et al. Expression of a gp 33/ 27000 MW activation inducer molecule (AIM) on human lymphoid tissues. Induction of cell proliferation on thymocytes and B lymphocytes by anti-AIM antibodies. Immunology 1989; 68: 72-79.
17. + T lymphocytes in viral chronic active hepatitis. Gastroenterol 1990; 98: 1029-1035.
18. Sancho D, Gómez M, Viedma F et al. CD69 downregulates autoimmune reactivity through active transforming growth factor-beta production in collagen-induced arthritis. J Clin Invest 2003; 112: 872-882.
19. Fernandez Herrera J, Fernandez-Ruiz E, Lopez-Cabrera M et al. CD69 expression and tumour necrosis factor-α immunoreactivity in the inflammatory cell infiltrate of halo naevi. Br J Dermatol 1996; 134: 388-393.
20. + T cells in lesional plaque psoriasis after clobetasol-17 propionate treatment. Acta Derm Venereol 2005; 85: 113-117.
21. Ferenczi K, Burack L, Pope M et al. CD69, HLA-DR and the IL-2R identify persistently activated T cells in psoriasis vulgaris lesional skin: blood and skin comparisons by flow cytometry. J Autoimmun 2000; 14: 63-78.
22. + T cells expressing early activation antigen CD69 in murine lupus: Possible abnormal regulatory role for cytokine imbalance. J Immunol 1998; 161: 1267-1273.
23. Hernández-García C. The CD69 activation pathway in rheumatoid arthritis synovial fluid T cells. Arthritis Rheum 1996; 39: 1277-1286.
24. Franks ME, Macpherson GR, Figg WD. Thalidomide. Lancet 2004; 363: 1802-1811.
25. Torres-Alvarez B, Castanedo-Cazares JP, Moncada B. Pentoxifylline in the treatment of actinic prurigo. Dermatology 2004; 208: 198-201.
26. Layseca-Espinoza E, Baranda L, Alvarado-Sanchez B et al. Rolipram inhibits polarization and migration of human T lymphocytes. J Invest Dermatol 2003; 121: 81-87.
27. Allen BR. Benoxaprofen and the skin. Br J Dermatol 1983; 109: 361-363.
28. Ellis CN, Goldfarb MT, Roenigk HH Jr et al. Effects of oral meclofenamate therapy in psoriasis. J Am Acad Dermatol 1986; 14: 49-52.